{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0000806\nAge: 61\nGender: Female\nSample ID: P-0000806-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Breast Invasive Cancer, NOS\nSample Type: Metastasis\nTumor Purity: 50.0%\n=============\nDNA Variants:\nBAP1 c.649G>A (p.A217T) - in 21.00% of 370 reads\nBCOR c.1619G>A (p.R540Q) - in 21.00% of 708 reads\nSMARCB1 c.713C>A (p.A238D) - in 15.00% of 412 reads\nCNA Data:\nCCND1 - High Level Amplification\nERBB2 - High Level Amplification\nERG - Homozygous Deletion\nCDK12 - High Level Amplification\nPAK1 - High Level Amplification\nFOXA1 - High Level Amplification\nEED - High Level Amplification\nFGF4 - High Level Amplification\nFGF3 - High Level Amplification\nFGF19 - High Level Amplification\nTMPRSS2 - Homozygous Deletion\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Invasive Cancer, NOS\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Margetuximab-cmkb + Chemotherapy\",\n    \"Prior Treatment or Resistance Status\": \"Received at least two prior anti-HER2 regimens, including for metastatic disease\",\n    \"Genomic Features\": \"ERBB2 high level amplification\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf\"\n  }\n}"
}